🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Peking University Shenzhen Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Peking University Shenzhen Hospital as lead sponsor. Synced 27 Sep 2026
11Current trials
8Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Peking University Shenzhen Hospital is the lead sponsor of 11 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Ciprofol, Dexmedetomidine and Esketamine. The most-studied condition is Vaginitis.

ClinicalTrials.gov trials by status

  • Recruiting873%
  • Not yet open218%
  • By invitation19%

Trials by phase

  • Not applicable436%
  • Observational436%
  • Phase 319%
  • Phase 419%
  • Phase EARLY_PHASE119%
01

Clinical trials sponsored by Peking University Shenzhen Hospital

11 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository
NCT04574089 · ClinicalTrials.gov ↗ · Vaginitis
Phase 3 Recruiting 2020-05 China
The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study
NCT07089173 · ClinicalTrials.gov ↗ · Hemodynamics
Not applicable Recruiting 2025-08 China
Incidence of Postoperative Cognitive Decline in Patients With Preexisting Cognitive Impairment
NCT07135336 · ClinicalTrials.gov ↗ · Cognitive and Behavioral Impairment
Observational Recruiting 2025-07 China
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
NCT07374614 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, ALK, Iruplinalkib
Observational Recruiting 2026-01 China
A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis
NCT04771728 · ClinicalTrials.gov ↗ · Bacterial Vaginosis
Phase 4 Recruiting 2020-02 China
Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality
NCT07002723 · ClinicalTrials.gov ↗ · Hip Fractures
Not applicable Recruiting 2025-06 China
Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients
NCT07004686 · ClinicalTrials.gov ↗ · Opioid Use
Not applicable Recruiting 2025-06 China
The Effective Blood Concentration of Ciprofol
NCT07294989 · ClinicalTrials.gov ↗ · Thyroid Disease
Drug: Ciprofol
Observational Recruiting 2025-07 China
Development of a Risk Prediction Model for Post-Spinal Anesthesia Hypotension During Cesarean Delivery Using Heart Rate, Blood Pressure, Perfusion Index, ECG Waveforms, and SpO₂ Waveforms
NCT07689825 · ClinicalTrials.gov ↗ · Cesarean Section
Observational Not yet open 2026-07 China
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
NCT07504445 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase EARLY_PHASE1 Not yet open 2026-06 China
Supraglottic Jet Oxygenation Ventilation During Hysteroscopic Surgery
NCT07110428 · ClinicalTrials.gov ↗ · Hysteroscopic Surgery
Not applicable By invitation 2025-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Peking University Shenzhen Hospital trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Peking University Shenzhen Hospital trials

14 conditions
Vaginitis1Hemodynamics1Cognitive and Behavioral Impairment1Cesarean Section1Non-Small Cell Lung Cancer1ALK1Iruplinalkib1Lorlatinib1Bacterial Vaginosis1Hip Fractures1Advanced Solid Tumors1Hysteroscopic Surgery1Opioid Use1Thyroid Disease1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China118

A trial with sites in more than one country appears in each of those registers.

05

Questions about Peking University Shenzhen Hospital trials

How many clinical trials does Peking University Shenzhen Hospital sponsor?

Peking University Shenzhen Hospital is the lead sponsor of 11 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Peking University Shenzhen Hospital trials recruiting?

Yes. 8 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Peking University Shenzhen Hospital testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Ciprofol (1), Dexmedetomidine (1), Esketamine (1), Lidocaine (1) and Sufentanil (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.